Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Your Article Summary
See Latest ArticlesMerck and Co., Inc. and Cardiome Sign License Agreement for Vernakalant, an Investigational Drug for Treatment of Atrial Fibrillation
Merck & Co., 04/09/09
Merck and Co., Inc. and Cardiome Pharma Corp. announced a collaboration and license agreement for the development and commercialization of vernakalant, an investigational candidate for the treatment of atrial fibrillation. The agreement provides Merck with exclusive global rights to the oral formulation of vernakalant for the maintenance of normal heart rhythm in patients with atrial fibrillation, and provides a Merck affiliate, Merck Sharp and Dohme GmbH, with exclusive rights outside of the United States, Canada and Mexico to the intravenous formulation of vernakalant for rapid conversion of acute atrial fibrillation to normal heart rhythm.
Today in Licensure/Accreditation...keeping you current
Receive free subspecialty "5-minute updates" via email
New ncqa disease management standards focus on measurement, quality improvement and transparency
National Committee for Quality Assurance (NCQA), 12/15/09
EDI Accrediting Firm Updates Criteria
HealthDataManagement, 12/09/09
Consumer Demand for H1N1 Information Highlights Importance of Accreditation for Health Call Centers
URAC News Releases, 12/07/09
Article Search
Sponsor